RxDoctor Payments Data

Sandra Henemyer

Family · Henderson, NVNPI 1215693379

Payments from drug & device makers

$604in general payments, 2019–2025

Across 24 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$177
  • Biohaven Pharmaceutical Holding Company Ltd.$165
  • AbbVie$104
  • Nalu Medical, Inc.$34
  • Lilly USA, LLC$27
  • Amgen$23
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$604 in reported general payments places this provider in the 60th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$29,641
Medicare patients
65
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide15$45,229
OzempicSemaglutide33$44,240
JardianceEmpagliflozin12$23,045
XareltoRivaroxaban39$21,988
Albuterol Sulfate HfaAlbuterol Sulfate49$2,144
Atorvastatin Calcium124$1,290
Levothyroxine Sodium97$908
Ibuprofen52$829
Omeprazole44$799
Rosuvastatin Calcium41$707
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$607
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$575
SynthroidLevothyroxine Sodium11$505
Losartan Potassium53$491
Sucralfate12$472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$177$89,46948 claims
Boehringer IngelheimJardiance$14$23,04512 claims
AbbVieSynthroid$104$50511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,501 family providers in Nevada.

Other family in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →